Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, 1000, Dhaka, Bangladesh.
Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207, Dhaka, Bangladesh.
Expert Rev Anti Infect Ther. 2022 Oct;20(10):1309-1332. doi: 10.1080/14787210.2022.2122442. Epub 2022 Sep 28.
Superbugs are microorganisms that cause disease and have increased resistance to the treatments typically used against infections. Recently, antibiotic resistance development has been more rapid than the pace at which antibiotics are manufactured, leading to refractory infections. Scientists are concerned that a particularly virulent and lethal 'superbug' will one day join the ranks of existing bacteria that cause incurable diseases, resulting in a global health disaster on the scale of the Black Death.
This study highlights the current developments in the management of antibiotic-resistant bacteria and recommends strategies for further regulating antibiotic-resistant microorganisms associated with the healthcare system. This review also addresses the origins, prevalence, and pathogenicity of superbugs, and the design of antibacterial against these growing multidrug-resistant organisms from a medical perspective.
It is recommended that antimicrobial resistance should be addressed by limiting human-to-human transmission of resistant strains, lowering the use of broad-spectrum antibiotics, and developing novel antimicrobials. Using the risk-factor domains framework from this study would assure that not only clinical but also community and hospital-specific factors are covered, lowering the chance of confounders. Extensive subjective research is necessary to fully understand the underlying factors and uncover previously unexplored areas.
超级细菌是指能够引起疾病且对通常用于治疗感染的药物具有耐药性的微生物。最近,抗生素耐药性的发展速度超过了抗生素的生产速度,导致了难治性感染。科学家们担心,有一天一种特别致命和致命的“超级细菌”将加入到现有的引起不治之症的细菌行列中,从而导致黑死病规模的全球健康灾难。
本研究强调了管理抗生素耐药细菌的最新进展,并建议了进一步规范与医疗保健系统相关的抗生素耐药微生物的策略。本综述还从医学角度探讨了超级细菌的起源、流行程度和致病性,以及针对这些不断增加的多药耐药生物的抗菌药物的设计。
建议通过限制耐药菌株在人与人之间的传播、降低广谱抗生素的使用以及开发新型抗菌药物来解决抗微生物药物耐药性问题。使用本研究中的风险因素领域框架将确保不仅涵盖临床因素,还涵盖社区和医院特定因素,从而降低混杂因素的可能性。需要进行广泛的主观研究,以充分了解潜在因素并揭示以前未探索的领域。